{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004669","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.367367+00:00","generated_at":"2026-05-31T10:05:20.008410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025","bullets":["Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.","Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.","Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.","Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.","Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004669","json":"https://secwatch.observer/filing/0001171843-24-004669.json","markdown":"https://secwatch.observer/filing/0001171843-24-004669.md","text":"https://secwatch.observer/filing/0001171843-24-004669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/0001171843-24-004669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/f8k_081024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:20.008410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}